Pipeline powered by groundbreaking glyco targeting engine
GO Therapeutics’ platform is continually generating new solid tumor targets, feeding a growing pipeline of novel cancer immuno-therapies.
ANTIBODY PROGRAM
MODALITIES
INDICATIONS
Mucins
GO-2
TCB
Solid Tumors
ANTIBODY PROGRAM
GO-2
MODALITIES
TCB
INDICATIONS
Solid Tumors
GO-2D5
TCB
Solid Tumors
ANTIBODY PROGRAM
GO-2D5
MODALITIES
TCB
INDICATIONS
Solid Tumors
Receptor Proteins
GO-4C8
CAR-T
Solid Tumors
ANTIBODY PROGRAM
GO-4C8
MODALITIES
CAR-T
INDICATIONS
Solid Tumors
GO-14C9
TCB
Solid Tumors
ANTIBODY PROGRAM
GO-14C9, GO-8H3
MODALITIES
CAR-T, TCB
INDICATIONS
Solid Tumors
GO-8H3
CAR-T
Lysomal
GO-3C7
ADC
Solid Tumors
ANTIBODY PROGRAM
GO-3C7
MODALITIES
ADC
INDICATIONS
Solid Tumors
ECM
GO-C15
Immunokine
Solid Tumors
ANTIBODY PROGRAM
GO-C15
MODALITIES
Immunokine
INDICATIONS
Solid Tumors
